Abstract
Background
Adrenocortical carcinoma (ACC), a rare and aggressive malignancy, accounts for up to14% of adrenal incidentalomas. The only chance of cure for ACC is diagnosis at an early stage; therefore, a main indication for adrenalectomy in patients with adrenal incidentaloma has been the potential risk of ACC. Recent studies suggest that this has led to earlier stage of ACC at diagnosis, more curative operations, and better survival.
Methods
We analyzed data on ACC from The National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database. Four equal time quartiles (1973–1979, 1980–1986, 1987–1993, and 1994–2000) were compared for changes in demographics, pathology, treatment, and cause-specific mortality.
Results
The average age was 51.2 years (range: 1–97), and 45.9% of patients were men. The average tumor size was 12 cm (range: 2–36 cm), and only 4.2% were ≤ 6 cm. Most (88%) patients had surgical resection of their tumor, and external beam radiotherapy was used in only 12% of patients. Between the time quartiles compared (as well as annually), there was no significant difference at presentation in age at diagnosis, sex, race/ethnicity, tumor size, tumor grade, the frequency of distant metastasis, and overall TNM stage. Low tumor grade, lower stage of ACC, later time quartile, and surgical resection were associated with a lower cause-specific mortality by univariate analysis (P ≤ 0.002) and by multivariate analysis (P ≤ 0.031).
Conclusions
Although adrenal incidentalomas have become a common indication for adrenalectomy, this has not resulted in patients with ACC being diagnosed earlier or treated at a lower stage of disease at the national level. The most important predictors of survival in these patients are tumor grade, tumor stage, and surgical resection.
Similar content being viewed by others
References
Sidhu S, Sywak M, Robinson B, et al. Adrenocortical cancer: recent clinical and molecular advances. Curr Opin Oncol 2004;16:13–18
Allolio B, Hahner S, Weismann D, et al. Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 2004;60:273–287
Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surg 2001;25:891–897
Kendrick ML, Lloyd R, Erickson L, et al. Adrenocortical carcinoma: surgical progress or status quo? Arch Surg 2001;136:543–549
Mansmann G, Lau J, Balk E, et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 2004;25:309–340
Chen DY, Sosa RE, Scherr DS. Treatment of adrenocortical carcinoma: contemporary outcomes. Curr Urol Rep 2004;5:65–72
Sturgeon C, Kebebew E. Laparoscopic adrenalectomy for malignancy. Surg Clin North Am 2004;84:755–774
Warren JL, Harlan LC. Can cancer registry data be used to study cancer treatment? Med Care 2003;41:1003–1005
Reynolds T. Report examines association between cancer and socioeconomic status. J Natl Cancer Inst 2003;95:1431–1433
Kadan-Lottick NS, Ness KK, Bhatia S, Gurney JG, et al. Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. J Am Med Assoc 2003;290:2008–2014
Gatta G, Ciccolallo L, Capocaccia R, et al. Differences in colorectal cancer survival between European and US populations: the importance of sub-site and morphology. Eur J Cancer 2003;39:2214–2222
http://www.seer.cancer.gov. Vol 2005
http://www.nci.nih.gov/cancertopics/pdq/treatment/adrenocortical/. Vol 2005
Tauchmanova L, Colao A, Marzano LA, et al. Andrenocortical carcinomas: twelve-year prospective experience. World J Surg 2004;28:896–903
Wajchenberg BL, Albergaria Pereira MA, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000;88:711–736
Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993;72:3145–3155
Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 2002;20:941–950
Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999;6:719–726
Tritos NA, Cushing GW, Heatley G, et al. Clinical features and prognostic factors associated with adrenocortical carcinoma: Lahey Clinic Medical Center experience. Am Surg 2000;66:73–79
Harrison LE, Gaudin PB, Brennan MF. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 1999;134:181–185
Haak HR, Cornelisse CJ, Hermans J, et al. Nuclear DNA content and morphological characteristics in the prognosis of adrenocortical carcinoma. Br J Cancer 1993;68:151–155
de Fraipont F, El Atifi M, Cherradi N, et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 2005;90:1819–1829
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kebebew, E., Reiff, E., Duh, QY. et al. Extent of Disease at Presentation and Outcome for Adrenocortical Carcinoma: Have We Made Progress?. World J. Surg. 30, 872–878 (2006). https://doi.org/10.1007/s00268-005-0329-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00268-005-0329-x